logo
logo

Hanbio Therapeutics Announces The Completion Of A Us$40 Million Series A Financing Led By Orbimed And Hankang Capital

Hanbio Therapeutics Announces The Completion Of A Us$40 Million Series A Financing Led By Orbimed And Hankang Capital

01/29/22, 10:37 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/CN.svgshanghai
Money raised
$40 million
Round Type
series a
HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series A financing to advance the preclinical and clinical development of its series of innovative antibodies and other biologics products. This round of financing was jointly led by OrbiMed and Hankang Capital, followed by Yonghua Investment and Elikon Investment. Before the completion of this round of financing, HanBio was an early product research and development company incubated by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian")

Company Info

Company
Han Bio Therapeutics
Location
shanghai, shanghai, china
Additional Info
"Transformative Medicines by Innovation." HanBio Therapeutics is an innovative biotechnology company committed to researching and developing next generation transformative medicines to treat patients with serious diseases. For more information, please contact:Zhenping Zhu, MD, PhDEmail: zhuzhenping@hanbiotx.com PR@hanbiotx.com Tel: +1 347 327 0705 (USA) +011 86 186 1234 0399 (China) SOURCE HanBio Therapeutics